Lots Of Merck-Specific News -- In Prior Comments, This Past Week...

Our comment box -- to the immediately prior post -- contains news stories from the past week. It was an unusually active news week, for Kenilworth. Do go check those out.

But I'll highlight the final EU and WHO global approvals of Merck's single dose Ebola vaccine -- to be called Ervebo^® [waiting on the graphical version of the trademark/logo, to add it to the image at right] -- as being the most monumental, for the eradication of suffering, and the advancement of global human health care.

. . . .Within 48 hours of the European Commission approving the vaccine earlier this week, the World Health Alliance (WHO) verified that the treatment also reached its health and safety standards for global use, making it the first vaccine with clinical efficacy to protect individuals 18 years of age or older at risk of infection with the Ebola virus. . . .

Data from clinical trials and compassionate use protocols have shown that Ervebo protects against Ebola virus disease in humans following a single-dose administration. . . .

Onward, to an exciting week ahead. Now you know.

नमस्ते